Molecular Diagnostics Market
Molecular Diagnostics Market – Size, Share, Growth, Trends, and Forecast (2025–2035): Global Industry Analysis by Product Type (Instruments, Reagents, Software and Services), Technology (PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification, Sequencing, DNA Microarrays, and Others), and Application (Infectious Diseases, Oncology and Genetic Testing, Women’s Health, Respiratory Infections, Neurological Diseases, and Others)
Published Date: November - 2025 | Publisher: MRA | No of Pages: 261 | Industry: Healthcare | Format:
Molecular
Diagnostics Market Summary
The global molecular diagnostics
market is experiencing strong growth driven by the increasing prevalence of
infectious diseases, cancer, and genetic disorders, alongside continuous
advancements in molecular testing technologies such as PCR, NGS, and AI-based
diagnostics.
Global
Molecular Diagnostics Market Highlights
- Market Value (2024)
US$ 16.6 Bn – Solid base for diagnostic innovation and adoption.
- Forecast Period
2025–2035 – Sustained growth driven by technological advancements.
- Expected CAGR
9.1% – Strong annual growth rate.
- Forecast Value (2035) US$ 43.4 Bn – Significant expansion through innovation
in molecular testing.
Expert
Insights and StrategicMolecular Diagnostics Market
The molecular diagnostics market
continues to advance rapidly due to rising cases of infectious and chronic
diseases and an increasing focus on early and precise diagnosis. Growing
awareness of genetic disorders and cancer detection has led to an upsurge in
demand for innovative testing technologies such as PCR, NGS, and liquid biopsy.
Technological progress is reshaping
diagnostic approaches, enabling more accurate and faster results while
supporting the rise of personalized medicine. With PCR and sequencing-based
tests becoming standard tools, molecular diagnostics are now pivotal for public
health, oncology, and infectious disease management.
While challenges persist—such as
high equipment costs, regulatory complexity, and limited skilled professionals
in developing regions—the trend toward point-of-care (POC) and companion
diagnostics is accelerating. The integration of molecular testing into
pharmaceutical and clinical workflows positions the market for long-term,
sustainable growth.
Market
Overview
Global
Molecular Diagnostics Market by Product Type
Molecular diagnostics involves
analyzing biological markers in the genome and proteome to detect and monitor
disease. The technology provides high precision, sensitivity, and rapid
results—crucial for infectious disease control, oncology, and genetic disorder
screening.
Applications span clinical
laboratories, hospitals, and home-testing kits, with continuous innovation in
instruments, reagents, and digital reporting systems. The use of AI and
automation is further enhancing testing efficiency and interpretation accuracy.
Key
Market Drivers
|
Attribute |
Detail |
|
Market Growth Drivers |
Rising Prevalence of Infectious
and Chronic Diseases, Technological Advances in PCR, NGS, Liquid Biopsy &
AI, Expansion of Point-of-Care Testing |
Rising
Prevalence of Infectious and Chronic Diseases to Drive Market Expansion
The growing global burden of chronic
and infectious diseases is a major catalyst for molecular diagnostics adoption.
Rapid detection is essential to reduce transmission and enable early treatment.
For instance, according to the U.S.
CDC (October 2024), 6 in 10 Americans live with at least one chronic condition,
while STIs exceeded 2.5 million cases in 2022. Molecular tests such as PCR are
vital tools in identifying and managing these conditions effectively.
Technological
Advancements in PCR, NGS, Liquid Biopsy & AI Boost Market Growth
Next-generation sequencing (NGS),
polymerase chain reaction (PCR), and liquid biopsy are revolutionizing disease
diagnostics. PCR remains the gold standard for identifying infectious agents,
while NGS and liquid biopsy enable comprehensive cancer and genetic testing
with minimal invasiveness.
AI-powered diagnostics are further
improving speed and accuracy by analyzing data sets in real-time and supporting
clinical decision-making. These technologies are expanding molecular
diagnostics beyond laboratories to remote and decentralized settings.
Reagents
Segment Dominating Molecular Diagnostics Market
Reagents represent the largest
revenue-generating segment due to their essential role in test accuracy and
repeat use. They are integral to molecular assays such as PCR and sequencing.
Continuous R&D has led to the
development of disease-specific reagent kits for early detection of conditions
like tuberculosis, hepatitis, and cancer. This segment’s growth is reinforced
by rising diagnostic testing demand and expanding applications in emerging
economies.
Regional
Outlook
|
Attribute |
Detail |
|
Leading Region |
North America |
North America leads the molecular
diagnostics market owing to advanced healthcare infrastructure, strong R&D
capabilities, and widespread adoption of cutting-edge technologies. The U.S.
and Canada are key contributors, driven by precision medicine initiatives,
government funding for diagnostic testing, and a strong presence of leading
biotech firms.
Competitive
Landscape
Key players are focusing on
technological innovation, product expansion, and strategic collaborations to
enhance diagnostic capabilities across multiple disease areas. Companies are
investing in digital PCR, AI-integrated testing platforms, and next-generation
molecular systems to strengthen their global footprint.
Prominent
Companies Operating in the Global Market
- F. Hoffmann-La Roche AG
- Abbott
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company (BD)
- bioMérieux
- DiaSorin S.p.A.
- Hologic, Inc.
- SD Biosensor, Inc.
- QIAGEN N.V.
- QuidelOrtho
- Siemens Healthineers AG
- Other Prominent Players
Key
Developments in the Market
- April 2025
Abbott launched its CE-marked HR HPV assay in Europe, offering
self-collection options and enhanced genotyping for high-risk HPV
detection.
- September 2024
QIAGEN introduced the QIAcuityDx Digital PCR System, enabling precise
DNA/RNA quantification for cancer monitoring and clinical diagnostics.
Molecular
Diagnostics Market Snapshot
|
Attribute |
Detail |
|
Market Size (2024) |
US$ 16.6 Bn |
|
Forecast Value (2035) |
US$ 43.4 Bn |
|
CAGR (2025–2035) |
9.1% |
|
Historical Data |
2020–2023 |
|
Quantitative Units |
US$ Bn |
|
Analysis Scope |
Segment and regional-level
assessment with qualitative insights on key drivers, restraints, and trends |
|
Competition Landscape |
Profiles of leading companies with
product portfolios, strategies, and global presence |
|
Format |
Electronic (PDF) + Excel |
Segmentation Overview
By
Product Type
- Instruments
- Reagents
- Software and Services
By
Technology
- PCR
- In Situ Hybridization (ISH)
- Isothermal Nucleic Acid Amplification
- Sequencing
- DNA Microarrays
- Others (Mass Spectrometry, Liquid Biopsy, etc.)
By
Application
- Infectious Diseases
- Sexual Health Diseases
- Women’s Health
- Blood-borne Virus
- Respiratory Infections
- Healthcare-associated Infections
- Oncology and Genetic Testing (Bladder, Breast, Prostate,
Colorectal, Lung, etc.)
- Neurological Diseases
- Others (Cardiovascular Diseases, etc.)
By
End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Research Institutes, etc.)
By
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Related Reports
Table of Content
Claim a Free Sample
Get a preview with key statistics, projections, and trends for this report. Ideal for quick insights.
Send Me a SampleNeed full access?
Purchase Report